Published in World J Gastroenterol on November 21, 2010
Activation of PI3K/AKT and MAPK pathway through a PDGFRβ-dependent feedback loop is involved in rapamycin resistance in hepatocellular carcinoma. PLoS One (2012) 1.05
Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition. Liver Cancer (2012) 0.98
Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma. World J Gastroenterol (2015) 0.87
Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies. Med Mol Morphol (2011) 0.84
Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review. World J Gastroenterol (2015) 0.77
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Hepatocellular carcinoma. Lancet (2003) 22.54
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol (2004) 4.67
Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology (2004) 2.91
Epidemiology of hepatocellular carcinoma in Hispanics in the United States. Arch Intern Med (2007) 2.54
A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology (2006) 2.32
Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9. Hepatol Res (2009) 1.70
Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J Hepatol (2007) 1.56
The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma. Med Oncol (2009) 1.46
Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer. Int J Clin Oncol (2008) 1.37
Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Cell Mol Med (2009) 1.30
Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation. Transplantation (2007) 1.29
RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma. J Cell Mol Med (2008) 1.19
Targeted agents for the treatment of advanced renal cell carcinoma. Curr Drug Targets (2005) 1.11
Systemic therapy for hepatocellular carcinoma. Cancer J (2008) 0.97
Liver transplantation for hepatocellular carcinoma: the Kyoto experience. J Hepatobiliary Pancreat Sci (2009) 0.90
Complete remission of postransplant lung metastases from hepatocellular carcinoma under therapy with sirolimus and mycophenolate mofetil. Transplantation (2005) 0.85
Sirolimus therapy in liver transplant patients: an initial experience at a single center. Transplant Proc (2008) 0.81
Pancreatic islet amyloidosis, beta-cell apoptosis, and alpha-cell proliferation are determinants of islet remodeling in type-2 diabetic baboons. Proc Natl Acad Sci U S A (2009) 1.45
Split-liver transplantation: results of statewide usage of the right trisegmental graft. Am J Transplant (2005) 1.19
Severe, late-onset graft-versus-host disease in a liver transplant recipient documented by chimerism analysis. Hum Immunol (2005) 0.93
Regional sharing for adult status 1 candidates: reduction in waitlist mortality. Liver Transpl (2006) 0.86
Evaluation of a model to predict poor survival in patients undergoing elective TIPS procedures. J Vasc Interv Radiol (2002) 0.82
Hepatocellular carcinoma and liver transplantation. Curr Opin Organ Transplant (2011) 0.80
Transjugular intrahepatic portosystemic shunt creation in a patient with situs inversus. J Vasc Interv Radiol (2002) 0.79
Use of a silastic silo for closure of the abdominal wall in a pediatric patient receiving a cadaveric split liver. J Pediatr Surg (2003) 0.75
Use of split-liver allografts does not impair pediatric recipient growth. Liver Transpl (2007) 0.75
Histologic changes resembling acute rejection in a liver transplant patient treated with terbinafine. Hum Pathol (2003) 0.75
Transjugular intrahepatic portosystemic shunt for variceal hemorrhage due to recurrent of hereditary hemorrhagic telangiectasia in a liver transplant. J Vasc Interv Radiol (2009) 0.75